Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, plans for a new $34 million extension to its state-of-the-art Madison, Wisconsin biologics manufacturing facility.
When completed, the additional 22,000 square feet of space will accommodate a new 2 x 2,000 liter single-use bioreactor system, allowing the company to support late-phase clinical and commercial production of up to 4,000 liter batches. The new footprint will also support expansion of analytical and process development laboratories, as well as additional office space.
The ground breaking ceremony, led by Lieutenant Governor of Wisconsin Rebecca Kleefisch and Catalent President and Chief Executive Officer John Chiminski, marks the beginning of construction at the site that will eventually create more than 100 new jobs.
The Wisconsin Economic Development Corporation (WEDC) has awarded Catalent with up to $1 million in state tax credits over the next three years. The actual amount of credits the company will receive is contingent upon the level of capital investment in Madison during the three-year period.
|Company Name||Catalent Pharma Solutions|
|Type||Expansion Of Biologics Manufacturing Facility|
|Estimated Cost||$34 Million|